Sermorelin corresponds to the biologically active N-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH). It binds the pituitary GHRH receptor, activating Gs/adenylate cyclase/cAMP ...
Sermorelin corresponds to the biologically active N-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH). It binds the pituitary GHRH receptor, activating Gs/adenylate cyclase/cAMP signaling that drives pulsatile growth hormone release, and has historically been used both as a diagnostic probe of pituitary GH reserve and as a chronic-dosing research tool for the GHRH axis.
Hormone Research · 1988
Evaluated chronic subcutaneous GHRH(1-29) dosing as a growth-promoting intervention in children with short stature.
View Source →European Journal of Pediatrics · 1986
In 131 children and adolescents, GRF(1-29)NH2 stimulation testing combined with basal IGF-1 measurement reliably distinguished GH-deficient from non-deficient children.
View Source →